An observational study in Sepsis and Community-Acquired Infections, sponsored by University of Oxford. Completed at 1 site in Thailand. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-13.
Sponsored by University of Oxford · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Sepsis by University of Oxford — none open to participants now, none under way, none of them phase 3. Sepsis · University of Oxford.
Among the 13 studies in Sepsis by University of Oxford, this one is one of 2 that started in 2018, is one of 9 observational ones, and was the 9th registered.
2,417 studies on the registry are indexed under Sepsis; 542 are open to participants now.
Browse Sepsis studies →None of the 13 studies in Sepsis by University of Oxford is open now. The open studies under Sepsis, anywhere →
Of the 318 Sepsis studies recruiting now, 213 (67%) set no upper age limit and 53 (17%) stop at 75 or younger; 68 take children under 18; 42 take healthy volunteers.
This study: 18 Years and older · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 1 · Phase 3 3
First in 2005; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,002 is above the median of 150 across 1,162 observational studies indexed under Sepsis.
Median enrollment 466 across the 4 interventional studies, 1,002 across the 9 observational. Of the 9 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Oxford is the lead sponsor of 813 studies on the registry; 120 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 13 studies in Sepsis by University of Oxford, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is an observational study to evaluate the utility of the latest recommendation to define severity of infection for sepsis patients (sepsis-3), and to identify the aetiology and factors associated with outcome of community-acquired sepsis in Northeast Thailand.
Potential study participants will be adult patients who are presented at the hospital with community-acquired sepsis. Clinical specimens (including blood, urine, sputum, throat swabs and pus or wound swab) will be collected from each participant on admission for culture, PCR and serological tests, and other laboratory tests. Participants' treatment will be closely monitored during the duration of their hospital stay. Blood will be again collected at 72 hours after admission. Participants will be contacted at 28 days after admission to determine clinical outcome by phone interview with standardized script.
Adult patients, both males and females, presenting with sepsis will be approached for participation in the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
qSOFA (quick Sepsis-related Organ Failure Assessment) score ≥ 2 defined as 2 or more of the following:
Exclusion Criteria:
Please note that the following conditions are not exclusion criteria, and patients with the following conditions can be enrolled into the study.
Adult patients, both males and females, presenting with sepsis will be approached for participation in the study.
Other: Specimens collection
On admission: Blood samples 30.01 mL and other specimens (if available) for culture and other diagnostics tests including sputum, throat swab, urine (midstream urine), and pus which is part of routine practice for patients with sepsis at study site. Day 3: Blood (15 mL) for culture (10 mL) and PCR (5 mL). There will be no blood collection, if patient is discharged before day 3.
28-day mortality after admission date
Time frame: 2.5 years
Causative organisms of community-acquired sepsis
Time frame: 2.5 years
Respiration: Blood gas (PaO2 [mmHg])
Clinical parameters evaluated as according to Sepsis-3 guideline; Sequential Organ Failure Assessment (SOFA)
Time frame: 2.5 years
Respiration: Type of oxygen support
Clinical parameters evaluated as according to Sepsis-3 guideline; Sequential Organ Failure Assessment (SOFA)
Time frame: 2.5 years
Respiration: FiO2 (% )
Clinical parameters evaluated as according to Sepsis-3 guideline; Sequential Organ Failure Assessment (SOFA)
Time frame: 2.5 years
Respiration: SpO2 by pulse oximeter level (%)
Clinical parameters evaluated as according to Sepsis-3 guideline; Sequential Organ Failure Assessment (SOFA)
Time frame: 2.5 years
Coagulation: Platelet (per μL)
Clinical parameters evaluated as according to Sepsis-3 guideline; Sequential Organ Failure Assessment (SOFA)
Time frame: 2.5 years
Liver: Total Bilirubin (mg/dL)
Clinical parameters evaluated as according to Sepsis-3 guideline; Sequential Organ Failure Assessment (SOFA)
Time frame: 2.5 years
Cardiovascular: Mean Arterial Pressure (MAP) at enrolment (mmHg)
Clinical parameters evaluated as according to Sepsis-3 guideline; Sequential Organ Failure Assessment (SOFA)
Time frame: 2.5 years
Cardiovascular: Dosages (μg/kg/min) of inotropic
Clinical parameters evaluated as according to Sepsis-3 guideline; Sequential Organ Failure Assessment (SOFA)
Time frame: 2.5 years
Cardiovascular: Dosages (μg/kg/min) of vasopressor agents
Clinical parameters evaluated as according to Sepsis-3 guideline; Sequential Organ Failure Assessment (SOFA)
Time frame: 2.5 years
Central nervous system: Glasgow Coma Score
Clinical parameters evaluated as according to Sepsis-3 guideline; Sequential Organ Failure Assessment (SOFA)
Time frame: 2.5 years
Renal: Creatinine (mg/sdL)
Clinical parameters evaluated as according to Sepsis-3 guideline; Sequential Organ Failure Assessment (SOFA)
Time frame: 2.5 years
Hematology
Other laboratory measurement
Time frame: 2.5 years
Blood chemistry
Other laboratory measurement
Time frame: 2.5 years
Causes of sepsis associated with mortality outcome in patients with community-acquired sepsis in northeast Thailand
Time frame: 2.5 years
Sepsis resuscitation associated with mortality outcome in patients with community-acquired sepsis in northeast Thailand
Time frame: 2.5 years
Antimicrobial treatment associated with mortality outcome in patients with community-acquired sepsis in northeast Thailand
Time frame: 2.5 years
Inflammatory associated with mortality outcome in patients with community-acquired sepsis in northeast Thailand
Time frame: 2.5 years
Genetics factors with mortality outcome in patients with community-acquired sepsis in northeast Thailand
Time frame: 2.5 years
Diagnostic tests for infection in community-acquired sepsis in NE Thailand
Time frame: 2.5 years
Ran from Feb 2018 to primary completion in Mar 2023, 61 months.
Of 492 non-industry observational studies under Sepsis, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 58. This study's 61 months is above that.
Counting every sponsor, half of 544 studies reached it within 27 months; a quarter within 12 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.